A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 882



Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott, Severine Bompoint, Adeera Levin, Meg J Jardine. Lancet Diabetes Endocrinol 2019
Times Cited: 178




List of shared articles



Times cited

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal,[...]. Circulation 2021
22

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
6

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Daniel V O'Hara, Thomas R Parkhill, Sunil V Badve, Min Jun, Meg J Jardine, Vlado Perkovic. Diabetes Obes Metab 2021
2

Echocardiographic measures and subsequent decline in kidney function in older adults: the Atherosclerosis Risk in Communities Study.
Junichi Ishigami, Lena Mathews, Manabu Hishida, Dalane W Kitzman, Josef Coresh, Scott D Solomon, Amil M Shah, Kunihiro Matsushita. Eur Heart J Cardiovasc Imaging 2021
0

SGLT2 inhibitors: a narrative review of efficacy and safety.
Donald S Nelinson, Jose M Sosa, Robert J Chilton. J Osteopath Med 2021
0

Treatments for NAFLD: State of Art.
Alessandro Mantovani, Andrea Dalbeni. Int J Mol Sci 2021
3

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
0

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
4